NCT07011550View on ClinicalTrials.gov

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2030

Conditions
Microsatellite-stable Colorectal CancerStandard of CareNivolumabBevacizumab
Interventions
DRUG

Nivolumab

Given by IV

DRUG

Bevacizumab

Given by IV

DRUG

BMS-986340

Given by IV

DRUG

Trifluridine + Tipiracil

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Strategic Alliance

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT07011550 - Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer | Biotech Hunter | Biotech Hunter